Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 2001, p. 1355-1359, Vol. 45, No. 5
Istituto di Malattie Infettive e Medicina
Pubblica1 and Centro Interdipartimentale
di Epidemiologia, Biostatistica e Informatica
Medica,3 Università degli Studi di Ancona,
Ancona, Italy; and University of Texas Health Science
Center at San Antonio and Audie Murphy Veterans Administration
Hospital, San Antonio, Texas2
Received 16 October 2000/Returned for modification 27 November
2000/Accepted 5 February 2001
A checkerboard methodology, based on standardized methods proposed
by the National Committee for Clinical Laboratory Standards for broth
microdilution antifungal susceptibility testing, was applied to study
the in vitro interactions of flucytosine (FC) and posaconazole (SCH
56592) (FC-SCH) against 15 isolates of Cryptococcus neoformans. Synergy, defined as a fractional inhibitory
concentration (FIC) index of <0.50, was observed for 33% of the
isolates tested. When synergy was not achieved, there was still a
decrease in the MIC of one or both drugs when they were used in
combination. Antagonism, defined as a FIC of >4.0, was not observed.
The in vitro efficacy of combined therapy was confirmed by quantitative
determination of the CFU of C. neoformans 486, an isolate
against which the FC-SCH association yielded a synergistic interaction.
To investigate the potential beneficial effects of this combination
therapy in vivo, we established two experimental murine models of
cryptococcosis by intracranial or intravenous injection of cells of
C. neoformans 486. At 1 day postinfection, the mice were
randomized into different treatment groups. One group each received
each drug alone, and one group received the drugs in combination. While
combination therapy was not found to be significantly more effective
than each single drug in terms of survival, tissue burden experiments confirmed the potentiation of antifungal activity with the combination. Our study demonstrates that SCH and FC combined are significantly more
active than either drug alone against C. neoformans in
vitro as well in vivo. These findings suggest that this therapeutic approach could be useful in the treatment of cryptococcal infections.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.5.1355-1359.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Interactions of Posaconazole and Flucytosine
against Cryptococcus neoformans
*
Corresponding author. Mailing address: Istituto di
Malattie Infettive e Medicina Pubblica, Azienda Ospedaliera Umberto
I°, Via Conca-Torrette, 60020, Ancona, Italy. Phone: 39. 71. 5963467. Fax: 39. 71. 5963468. E-mail: cmalinf{at}popcsi.unian.it.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |